Middle East Molecular Diagnostics Market Growth, Business Opportunities, Share Value & Key Insights

Diagnostics is a well-developed market with an integral part of medical decision-making -aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare. Molecular diagnostics has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the Middle East molecular diagnostics market offer products encompassing the kits and reagents, instruments, and software categories.

The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the forecast period 2021-2031. The growth in the Middle East molecular diagnostics market is expected to be driven by factors such as the increasing prevalence of infectious diseases and various types of cancer in the Middle East, rising awareness of personalized medicine and its acceptance, coupled with the significant number of funding for executing RD in Middle East region.

Impact of COVID-19

The current Middle East molecular diagnostics market comprises software, instruments, and consumables. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, that have led to reduced usage of instruments, consumables, and software related to research. Overall, the impact of COVID-19 on the Middle East molecular diagnostics market size has been low-moderate. Some of the market players have reported a slight decline in sales. However, financials are already on their way to recovery. The decline in revenues was mostly a result of the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thus interrupting the supply chain. The timeline of impact spanned the end of the first quarter and the second quarter of 2020 for most of the key markets across the Middle East. However, the pandemic has played a key role in enhancing the growth prospects of molecular diagnostics and is expected to indirectly aid in improving the market growth outlook.

Market Segmentation

Middle East Molecular Diagnostics Market

Segmentation 1: by Product
• Systems
• Kits and Consumables
• Software and Other Products

The Middle East molecular diagnostics market in the products segment is expected to be dominated by the kits and consumables segment. This is due to an increasing number of molecular diagnostics kit providers offering kits and services to their end users.

Segmentation 2: by Testing Location
• Laboratory Testing
• Point-of-Care Testing

The Middle East molecular diagnostics market is dominated by the laboratory testing segment owing to an increasing number of molecular diagnostic laboratories in the Middle East region involved in undertaking various routine testing for different chronic and acute diseases.

Segmentation 3: by Technology
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Microarray
• In-Situ Hybridization (ISH)
• Immunohistochemistry (IHC)
• Other Technologies

The polymerase chain reaction segment dominates the Middle East molecular diagnostics market due to the increasing number of PCR testing being carried out in the Middle East laboratories for diagnosis.

Segmentation 4: by Application
• Core Molecular Diagnostics
• Reproductive Genetics
• Companion Diagnostics
• Liquid Biopsy
• Others

Segmentation 5: by End User
• Hospitals
• Diagnostic Centres
• Outpatient Clinics/General Practitioners
• Research Laboratories
• Others

Segmentation 6: by Country
o Kingdom of Saudi Arabia (K.S.A.)
o Israel
o United Arab Emirates (U.A.E.)
o Egypt
o Iran
o Qatar
o Other Countries

K.S.A. generated the highest revenue of $132.5 million in 2020. The Kingdom of Saudi Arabia (K.S.A.) has a huge population base suffering from various diseases and rising healthcare costs in the region. Medical research in the Kingdom of Saudi Arabia (K.S.A.) has gained momentum since 2013 and is heavily being invested in by the local government. The government is extensively supporting research organizations with projects aimed at improving the understanding and treatment of diseases affecting the Saudi population.

Recent Developments in Middle East Molecular Diagnostics Market

• In January 2022, Abbott showcased its life-changing diagnostic tools and medical devices product portfolio for point-of-care testing (POCT) that helped COVID-19, diabetes, and cardiovascular disease patients at MEDLAB Middle East.
• In June 2021, biomeruix launched EPISEQ SARS-COV-2 to identify SARS-CoV-2 variants using samples from COVID-19 positive patients.
• In 2021, the BD. company declared the approval of the BD Veritor At-Home COVID-19 Test for the detection of SARS-CoV-2 with definitive digital results at home.
• In 2020, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc., a Middle East leader in multiplex molecular diagnostics, for the commercialization and clinical development of molecular diagnostic products.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Abbott
• Agilent Technologies, Inc.
• bioMérieux SA
• BD
• Babirus Medical Equipment LLC
• Bio-Rad Laboratories, Inc.
• Danaher
• F. Hoffmann-La Roche Ltd.
• Guardant Health
• Illumina, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Companies that are not a part of the above-mentioned pool have been well represented across different sections of the report (wherever applicable).

Key Questions Answered in the Report

How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
Product (systems, kits and consumables, and software and other products)
Testing location (laboratory testing and point-of-care testing)
Technology (next-generation technology, polymerase chain reaction, immunohistochemistry, isothermal nucleic acid amplification technology, microarray, in-situ hybridization, and other technologies)
Application (core molecular diagnostics, reproductive genetics, companion diagnostics, liquid biopsy, and other applications)
End user (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)
Country (Kingdom of Saudi Arabia, Israel, Qatar, UAE, Egypt, Iran, and Rest-of-Middle East Countries)
What are the major market drivers, challenges, and opportunities in the Middle East molecular diagnostics market?
What are the underlying structures resulting in the emerging trends within the Middle East molecular diagnostics market?
How is each segment of the Middle East molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
What are the key development strategies implemented by the major players to sustain in the competitive market?
What are the key regulatory implications in developed and developing regions for molecular diagnostics?
Who are the leading players with significant offerings to the Middle East molecular diagnostics market? What is the current market dominance for each of these leading players?
What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type is anticipated to have the most promising growth?
What are the key applications in the Middle East molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
What are the major technologies that are employed in the Middle East molecular diagnostics market? Which is the dominating technology?
Who are the primary end users of the Middle East molecular diagnostics market? Which is the fastest-growing end-use segment in the Middle East molecular diagnostics market?
Who are the key manufacturers in the Middle East molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
What is the scope of the Middle East molecular diagnostics market? Which molecular diagnostics application and end user dominate this region?
What are the emerging trends in the Middle East molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
Which technologies are anticipated to break through the current molecular diagnostic regime?
Which companies are anticipated to be highly disruptive in the future and why?
What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?